若年性黄斑変性症（シュタルガルト病）治療の世界市場（～2026年）

• 英文タイトル：Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12456
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は若年性黄斑変性症（シュタルガルト病）治療のグローバル市場について調査・分析したレポートです。種類別（幹細胞治療、遺伝子治療、その他）市場規模、用途別（病院、眼科クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別若年性黄斑変性症（シュタルガルト病）治療の競争状況、市場シェア
・世界の若年性黄斑変性症（シュタルガルト病）治療市場：種類別市場規模 2015年-2020年（幹細胞治療、遺伝子治療、その他）
・世界の若年性黄斑変性症（シュタルガルト病）治療市場：種類別市場規模予測 2021年-2026年（幹細胞治療、遺伝子治療、その他）
・世界の若年性黄斑変性症（シュタルガルト病）治療市場：用途別市場規模 2015年-2020年（病院、眼科クリニック、その他）
・世界の若年性黄斑変性症（シュタルガルト病）治療市場：用途別市場規模予測 2021年-2026年（病院、眼科クリニック、その他）
・北米の若年性黄斑変性症（シュタルガルト病）治療市場分析：米国、カナダ
・ヨーロッパの若年性黄斑変性症（シュタルガルト病）治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの若年性黄斑変性症（シュタルガルト病）治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の若年性黄斑変性症（シュタルガルト病）治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの若年性黄斑変性症（シュタルガルト病）治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Sanofi、Bayer、Roche、Pfizer、Allergan、Gilead Sciences、Kubota Pharmaceutical、Alkeus Pharmaceuticals、Astellas Pharma、Ferrer Corporate
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.
Asia Pacific is expected to be the fastest growing market owing to the availability of skilled professional such as ophthalmologist, and eye surgeons. Additionally, improving healthcare infrastructure in developing countries like India is further fuelling the growth of juvenile macular degeneration market. China and India contribute to the growth of the market.

Market Analysis and Insights: Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
The global Juvenile Macular Degeneration (Stargardt Disease) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Scope and Market Size
Juvenile Macular Degeneration (Stargardt Disease) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Sanofi
Bayer
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate

Market segment by Type, the product can be split into
Stem Cell Therapy
Gene Therapy
Others
Market segment by Application, split into
Hospitals
Eye Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue
1.4 Market by Type
1.4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Stem Cell Therapy
1.4.3 Gene Therapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Eye Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Perspective (2015-2026)
2.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Growth Trends by Regions
2.2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Juvenile Macular Degeneration (Stargardt Disease) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Market Size
3.1.1 Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Revenue (2015-2020)
3.1.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Concentration Ratio
3.2.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in 2019
3.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players Head office and Area Served
3.4 Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Solution and Service
3.5 Date of Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)
5.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
6.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in North America (2019-2020)
6.3 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
6.4 North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
7.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Europe (2019-2020)
7.3 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
7.4 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
8.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in China (2019-2020)
8.3 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
8.4 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
9.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Japan (2019-2020)
9.3 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
9.4 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
10.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
11.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in India (2019-2020)
11.3 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
11.4 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)
12.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Sanofi
13.1.1 Sanofi Company Details
13.1.2 Sanofi Business Overview
13.1.3 Sanofi Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.1.4 Sanofi Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020))
13.1.5 Sanofi Recent Development
13.2 Bayer
13.2.1 Bayer Company Details
13.2.2 Bayer Business Overview
13.2.3 Bayer Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.2.4 Bayer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.2.5 Bayer Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.3.4 Roche Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.4.4 Pfizer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Allergan
13.5.1 Allergan Company Details
13.5.2 Allergan Business Overview
13.5.3 Allergan Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.5.4 Allergan Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.5.5 Allergan Recent Development
13.6 Gilead Sciences
13.6.1 Gilead Sciences Company Details
13.6.2 Gilead Sciences Business Overview
13.6.3 Gilead Sciences Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.6.4 Gilead Sciences Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.6.5 Gilead Sciences Recent Development
13.7 Kubota Pharmaceutical
13.7.1 Kubota Pharmaceutical Company Details
13.7.2 Kubota Pharmaceutical Business Overview
13.7.3 Kubota Pharmaceutical Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.7.4 Kubota Pharmaceutical Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.7.5 Kubota Pharmaceutical Recent Development
13.8 Alkeus Pharmaceuticals
13.8.1 Alkeus Pharmaceuticals Company Details
13.8.2 Alkeus Pharmaceuticals Business Overview
13.8.3 Alkeus Pharmaceuticals Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.8.4 Alkeus Pharmaceuticals Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.8.5 Alkeus Pharmaceuticals Recent Development
13.9 Astellas Pharma
13.9.1 Astellas Pharma Company Details
13.9.2 Astellas Pharma Business Overview
13.9.3 Astellas Pharma Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.9.4 Astellas Pharma Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.9.5 Astellas Pharma Recent Development
13.10 Ferrer Corporate
13.10.1 Ferrer Corporate Company Details
13.10.2 Ferrer Corporate Business Overview
13.10.3 Ferrer Corporate Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction
13.10.4 Ferrer Corporate Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)
13.10.5 Ferrer Corporate Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue
Table 3. Ranking of Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Stem Cell Therapy
Table 6. Key Players of Gene Therapy
Table 7. Key Players of Others
Table 8. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2015-2020)
Table 12. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Juvenile Macular Degeneration (Stargardt Disease) Treatment Players
Table 19. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Players (2015-2020)
Table 21. Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment as of 2019)
Table 22. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product Solution and Service
Table 25. Date of Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Share by Type (2015-2020)
Table 29. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Share by Application (2015-2020)
Table 31. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 35. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 37. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 41. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 43. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 47. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 49. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 53. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 55. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 59. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 65. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 67. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share (2019-2020)
Table 71. Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2020)
Table 75. Sanofi Company Details
Table 76. Sanofi Business Overview
Table 77. Sanofi Product
Table 78. Sanofi Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 79. Sanofi Recent Development
Table 80. Bayer Company Details
Table 81. Bayer Business Overview
Table 82. Bayer Product
Table 83. Bayer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 84. Bayer Recent Development
Table 85. Roche Company Details
Table 86. Roche Business Overview
Table 87. Roche Product
Table 88. Roche Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 89. Roche Recent Development
Table 90. Pfizer Company Details
Table 91. Pfizer Business Overview
Table 92. Pfizer Product
Table 93. Pfizer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 94. Pfizer Recent Development
Table 95. Allergan Company Details
Table 96. Allergan Business Overview
Table 97. Allergan Product
Table 98. Allergan Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 99. Allergan Recent Development
Table 100. Gilead Sciences Company Details
Table 101. Gilead Sciences Business Overview
Table 102. Gilead Sciences Product
Table 103. Gilead Sciences Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 104. Gilead Sciences Recent Development
Table 105. Kubota Pharmaceutical Company Details
Table 106. Kubota Pharmaceutical Business Overview
Table 107. Kubota Pharmaceutical Product
Table 108. Kubota Pharmaceutical Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 109. Kubota Pharmaceutical Recent Development
Table 110. Alkeus Pharmaceuticals Business Overview
Table 111. Alkeus Pharmaceuticals Product
Table 112. Alkeus Pharmaceuticals Company Details
Table 113. Alkeus Pharmaceuticals Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 114. Alkeus Pharmaceuticals Recent Development
Table 115. Astellas Pharma Company Details
Table 116. Astellas Pharma Business Overview
Table 117. Astellas Pharma Product
Table 118. Astellas Pharma Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 119. Astellas Pharma Recent Development
Table 120. Ferrer Corporate Company Details
Table 121. Ferrer Corporate Business Overview
Table 122. Ferrer Corporate Product
Table 123. Ferrer Corporate Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020) (Million US$)
Table 124. Ferrer Corporate Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Stem Cell Therapy Features
Figure 3. Gene Therapy Features
Figure 4. Others Features
Figure 5. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Eye Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Juvenile Macular Degeneration (Stargardt Disease) Treatment Report Years Considered
Figure 10. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Players in 2019
Figure 15. Global Top Juvenile Macular Degeneration (Stargardt Disease) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue in 2019
Figure 17. North America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

以下、関連資料のご紹介

若年性黄斑変性症治療の世界市場（～2026年）

Global Juvenile Macular Degeneration Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12457 2020年11月25日 99Pages
当調査資料は若年性黄斑変性症治療のグローバル市場について調査・分析したレポートです。種類別（アバシンカプタドペゴルナトリウム、エコーチオフェートヨウ化物、エミクススタト塩酸塩、FAB-111、その他）市場規模、用途別（クリニック、病院、在宅医療）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイ...

加齢黄斑変性症（AMD）遺伝子治療の世界市場（～2026年）

Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2020-2026
MRC2-11QY12018 2020年11月25日 97Pages
当調査資料は加齢黄斑変性症（AMD）遺伝子治療のグローバル市場について調査・分析したレポートです。種類別（網膜下、硝子体内）市場規模、用途別（単剤療法、併用療法）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

黄斑変性症（AMD）の世界市場（～2026年）

Global Macular Degeneration Drugs Market Size, Status and Forecast 2020-2026
MRC2-11QY12570 2020年11月25日 96Pages
当調査資料は黄斑変性症（AMD）のグローバル市場について調査・分析したレポートです。種類別（ルセンティス、アイレア、アバスチン、スクアラミン、コンセプト、ランパリザマブ、その他）市場規模、用途別（50〜60歳、60〜70歳、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...

黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の世界市場（～2026年）

Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size, Status and Forecast 2020-2026
MRC2-11QY12569 2020年11月25日 93Pages
当調査資料は黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬のグローバル市場について調査・分析したレポートです。種類別（黄斑変性症治療薬、糖尿病性網膜症治療薬）市場規模、用途別（50〜60歳、60〜70歳、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリ...

加齢性黄斑変性症の世界市場（～2026年）

Global Age-related Macular Degeneration Market Size, Status and Forecast 2020-2026
MRC2-11QY13611 2020年11月30日 98Pages
当調査資料は加齢性黄斑変性症のグローバル市場について調査・分析したレポートです。種類別（ウェット型AMD、ドライ型AMD）市場規模、用途別（ドラッグストア、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...

加齢性黄斑変性症（AMD）の世界市場（～2026年）

Global Wet Age Related Macular Degeneration (AMD) Market Size, Status and Forecast 2020-2026
MRC2-11QY05076 2020年11月20日 96Pages
当調査資料は加齢性黄斑変性症（AMD）のグローバル市場について調査・分析したレポートです。種類別（湿式加齢性黄斑変性症（湿式AMD）、乾式加齢性黄斑変性症（乾式AMD））市場規模、用途別（75歳以上、60歳以上、40歳以上）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

炎症性腸疾患（IBD）治療の世界市場（～2026年）

Global Inflammatory Bowel Disease (IBD) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12375 2020年11月25日 95Pages
当調査資料は炎症性腸疾患（IBD）治療のグローバル市場について調査・分析したレポートです。種類別（TNF阻害剤、アミノサリチル酸塩、免疫調節剤、コルチコステロイド）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタ...

筋萎縮性側索硬化症（ルーゲーリック病）治療の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY10827 2020年11月25日 93Pages
当調査資料は筋萎縮性側索硬化症（ルーゲーリック病）治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、幹細胞治療）市場規模、用途別（病院、診断センター、診療所、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

移植片対宿主病（GVHD）治療の世界市場（～2026年）

Global Graft Versus Host Disease (GVHD) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12072 2020年11月25日 134Pages
当調査資料は移植片対宿主病（GVHD）治療のグローバル市場について調査・分析したレポートです。種類別（モノクローナル抗体、MTOR阻害剤、チロシンキナーゼ阻害剤、サリドマイド、エタネルセプト）市場規模、用途別（急性移植片対宿主病（aGvHD）、慢性移植片対宿主病（cGvHD））市場規模、地域別（北米...

糖尿病性黄斑浮腫治療の世界市場（～2026年）

Global Diabetic Macular Edema Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11632 2020年11月25日 94Pages
当調査資料は糖尿病性黄斑浮腫治療のグローバル市場について調査・分析したレポートです。種類別（レーザー光凝固療法、薬物療法、ベバシズマブ、ラニビズマブ、トリアムシノロン）市場規模、用途別（病院、眼科クリニック、研究所、委託研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イ...

若年性黄斑変性症治療の世界市場（～2026年） Market Analysis and Insights: Global Juvenile Macular Degeneration Treatment Market The global Juvenile Macular Degeneration Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Juvenile Macular Degeneration Treat…
加齢黄斑変性症（AMD）遺伝子治療の世界市場（～2026年） Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is dire…
黄斑変性症（AMD）の世界市場（～2026年） Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. The North American region is the most lucrative market, ow…
黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の世界市場（～2026年） Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which b…
加齢性黄斑変性症の世界市場（～2026年） Market Analysis and Insights: Global Age-related Macular Degeneration Market The global Age-related Macular Degeneration market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Age-related Macular Degeneration Scope and Market…